Business
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
QUEENSBURY, N.Y., July 29, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA.
About this update from Delcath Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/920d4528e54e0ba84d6f7b6375d86281"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v4Vh4ZKfByYihhrcbUVANg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/920d4528e54e0ba84d6f7b6375d86281","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sS2jjZemnfwdpG0RnFYS6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/920d4528e54e0ba84d6f7b6375d86281","width":1024,"height":512}},"lazy":false},{"type":"text","content":"QUEENSBURY, N.Y., July 29, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA.","length":371,"tagName":"p"},{"type":"text","content":"About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT","length":53,"tagName":"p"},{"type":"text","content":"Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.","length":479,"tagName":"p"},{"type":"text","content":"In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentiall...